Science News
from research organizations

Histone deacetylase 6 inhibition enhances oncolytic viral therapy

Date:
October 20, 2015
Source:
Journal of Clinical Investigation
Summary:
Inhibition of histone deaceteylase 6 improves the ability of oncolytic herpes simplex virus type 1 to kill glioma cells, a new study indciates.
Share:
FULL STORY

Gliomas are extremely aggressive brain tumors that are resistant to standard cancer therapeutics. Oncolytic viral (OV) therapy, which uses engineered viruses to infect and target tumor cells for destruction by the immune system, is currently being explored for use in refractory cancers.

A new study in the Journal of Clinical Investigation indicates that inhibition of histone deaceteylases (HDACs) improves the ability of oncolytic herpes simplex virus type 1 (oHSV-1) to kill glioma cells. Antonio Chiocca and colleagues at Brigham and Women's Hospital showed that oHSV-1 enters glioma cells through endocytosis and traffics to lysosomes where it is degraded.

However, treatment of cells with HDAC inhibitors, especially HDAC6 inhibitors, increased shuttling of oHSV-1 to the nucleus where the virus could replicate and initiate tumor cell death. Importantly, HDAC inhibition increased the oHSV-1 levels both in a mouse glioma model and in glioma stem-like cells from patients.

These data suggest that the efficacy of OV therapies may be enhanced when used in combination with inhibitors of HDACs or other proteins that modulate cellular trafficking of these therapeutic viruses.


Story Source:

Materials provided by Journal of Clinical Investigation. Note: Content may be edited for style and length.


Journal Reference:

  1. Hiroshi Nakashima, Johanna K. Kaufmann, Pin-Yi Wang, Tran Nguyen, Maria-Carmela Speranza, Kazue Kasai, Kazuo Okemoto, Akihiro Otsuki, Ichiro Nakano, Soledad Fernandez, William F. Goins, Paola Grandi, Joseph C. Glorioso, Sean Lawler, Timothy P. Cripe, E. Antonio Chiocca. Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. Journal of Clinical Investigation, 2015; DOI: 10.1172/JCI80713

Cite This Page:

Journal of Clinical Investigation. "Histone deacetylase 6 inhibition enhances oncolytic viral therapy." ScienceDaily. ScienceDaily, 20 October 2015. <www.sciencedaily.com/releases/2015/10/151020191659.htm>.
Journal of Clinical Investigation. (2015, October 20). Histone deacetylase 6 inhibition enhances oncolytic viral therapy. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2015/10/151020191659.htm
Journal of Clinical Investigation. "Histone deacetylase 6 inhibition enhances oncolytic viral therapy." ScienceDaily. www.sciencedaily.com/releases/2015/10/151020191659.htm (accessed May 23, 2017).

RELATED STORIES